弥漫性大B细胞淋巴瘤的治疗最新进展

Recent advances in treatment of diffuse large B-cell lymphoma

二维码有效期 120s

摘要弥漫性大B细胞淋巴瘤(DLBCL)是一组具有生物学异质性的B细胞恶性肿瘤.CD20单克隆抗体(如利妥昔单抗)的应用使得DLBCL患者的预后得到明显改善,但是仍有部分患者应用联合利妥昔单抗的化疗方案后疗效不佳.因此,根据DLBCL的不同亚型及细胞起源,选择不同的治疗方案,成为目前DLBCL治疗关注的重点.本文就DLBCL的亚型及细胞起源等方面,总结DLBCL治疗方法及其预后研究的最新进展.

abstractsDiffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of B-cell malignancies.The usage of CD20 monoclonal antibody (eg.rituximab) has greatly improved the prognosis of DLBCL.However,some cases still have poor prognosis by chemotherapy combined with rituximab.Choosing different therapy methods according to different subtypes and cell of origin of DLBCL have become the key point.This review will discuss the therapy and prognosis of DLBCL on the aspect of different subtypes and cell of origin in DLBCL.

作者王清云 ^[1] 岑溪南 ^[1] 任汉云 ^[1] 学术成果认领

作者单位 100034,北京大学第一医院血液内科 ^[1]

关键词淋巴瘤,大B-细胞,弥漫性淋巴瘤,非霍奇金药物疗法预后双重打击淋巴瘤 Lymphoma,large B-cell,diffuse Lymphoma,non-Hodgkin Drug therapy Prognosis Double hit lymphoma

主题词淋巴瘤(Lymphoma)细胞(Cells)性(Sex)预后(Prognosis)金(Gold)

栏目名称述评

DOI 10.3760/cma.j.issn.1673-419X.2017.01.010

发布时间 2017-04-17

基金项目

北京市科委首都临床特色应用研究专项资助课题(Z141107002514017)Project Supported by Special Program for Capital Clinical Features Application Research of Beijing Municipal Science and Technology Commission